Humalog(insulin lispro)
Admelog, Humalog, Insulin Lispro, Liprolog, Liumjev, Lyumjev (insulin lispro) is a protein pharmaceutical. Insulin lispro was first approved as Humalog on 1996-04-30. It is used to treat hyperglycemia, type 1 diabetes mellitus, and type 2 diabetes mellitus in the USA. It has been approved in Europe to treat diabetes mellitus.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Admelog, Humalog, Lyumjev (discontinued: Humalog, Lyumjev)
CombinationsHumalog mix (discontinued: Humalog mix)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin lispro
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Humalog | insulin lispro | Eli Lilly | N-20563 RX | 1996-06-14 | 5 products |
| Humalog | insulin lispro | Eli Lilly | N-205747 RX | 2015-05-26 | 2 products |
| Lyumjev | insulin lispro-aabc | Eli Lilly | N-761109 RX | 2020-06-15 | 4 products |
| Admelog | insulin lispro | Sanofi | N-209196 RX | 2017-12-11 | 3 products |
Show 2 discontinued
Insulin lispro
+
Insulin lispro protamine
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| admelog | Biologic Licensing Application | 2025-10-01 |
| humalog | Biologic Licensing Application | 2025-04-01 |
| humalog 70/30 | New Drug Application | 2010-11-05 |
| humalog humalogpen | New Drug Application | 2011-12-20 |
| humalog mix50/50 | 2007-09-25 | |
| humalog mix75/25 | 2009-03-30 | |
| humalog mix75/25 humalog mix75/25 kwikpen humalog mix75/25 pen | New Drug Application | 2009-03-16 |
| humalog sterile diluent | Biologic Licensing Application | 2025-06-17 |
| insulin lispro | Biologic Licensing Application | 2024-05-31 |
| insulin lispro insulin lispro | Biologic Licensing Application | 2024-08-06 |
Show 3 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
| type 1 diabetes mellitus | EFO_0001359 | D003922 | E10 |
| hyperglycemia | — | D006943 | R73.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10A: Insulins and analogues
— A10AB: Insulins and analogues for injection, fast-acting
— A10AB04: Insulin lispro
— A10AC: Insulins and analogues for injection, intermediate-acting
— A10AC04: Insulin lispro
— A10AD: Insulins and analogues for injection used in diabetes, intermediate- or long-acting combined with fast-acting
— A10AD04: Insulin lispro
HCPCS
No data
Clinical
Clinical Trials
374 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 4 | — | 5 | 3 | 2 | 14 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 3 | — | 5 | 3 | 1 | 12 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | 3 | 3 | — | 7 |
| Hyperglycemia | D006943 | — | R73.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gestational diabetes | D016640 | — | O24.4 | — | 1 | — | — | — | 1 |
| Pregnancy in diabetics | D011254 | — | O24.91 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Insulin lispro |
| INN | insulin lispro |
| Description | Insulin lispro recombinant |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | 5UDP, 6NWV |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201538 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00046 |
| UNII ID | GFX7QIS1II (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Humalog – Eli Lilly
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Insulin lispro
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,214 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
94,791 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use